Monopar Therapeutics MNPR Proceeds from maturities of short-term investments

Proceeds from maturities of short-term investments at other companies

Air Products and ChemicalsAPD

$0-100%

Clover Health InvestmentsCLOV

$2.86M-88.9%

BILL HoldingsBILL

$465.88M-25.4%

Flywire CorporationFLYW

$11.27M-88.6%

FabrinetFN

$112.11M+180%

Lyft, Inc.LYFT

$0-100%

Revenue-—

Operating income-$5.2M-62.2%

Net income-$3.9M-48.3%

EPS (diluted)-$0.19—

Cash & equivalents$52.5M+32.3%

Total debt$230.4K+2,692%

Total equity$135.4M+153%

Total assets$138.0M+150%

Operating cash flow-$3.5M+38.7%

Market cap$587.04M+192%

Enterprise value$534.72M+232%

Return on equity-15.9%-6.6pp

Debt / equity0×0.0×

Current ratio56×—

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Monopar Therapeutics's proceeds from maturities of short-term investments?: Monopar Therapeutics (MNPR) reported proceeds from maturities of short-term investments of $35.25M in Q1 2026.
How has Monopar Therapeutics's proceeds from maturities of short-term investments changed year-over-year?: Monopar Therapeutics's proceeds from maturities of short-term investments increased by 2103.4% year-over-year, from $1.6M to $35.25M.